Myocardial Infarction Research
Myocardial infarction (MI) - more commonly referred to as a heart attack - is an acute event caused by the interruption of blood supply to regions of the heart, leading to myocardial necrosis. Infarction of a substantial area of the myocardium can disrupt normal conductance of the heart, leading to cardiac arrest.In the majority of cases, an MI is immediately preceded by the presence of an occlusive thrombus within a coronary artery, blocking blood flow to the downstream tissue. The most common cause of an occlusive thrombus within a coronary artery is the rupture of an atherosclerotic plaque. However, the occlusion of a coronary artery may also result from coronary embolism. This can occur in patients following stent placement, angioplasty, and coronary artery bypass grafting.
Myocardial Infarction Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Voltage-gated Calcium Channel (CaV) (38)
- Cell Adhesion Molecule (21)
- Others (10)
- Cyclooxygenase (24)
- Epithelial Sodium Channel (3)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Angiotensin-Converting Enzyme (8)
- IP3 Receptor (2)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Inward Rectifier Potassium (Kir) Channel (21)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Stem Cell Differentiation (54)
- Delta opioid receptor (16)
- Cathepsin (9)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Prostanoid Receptor (24)
Products for Myocardial Infarction Research - Page 40
- Cat.No. Product Name Information/Activity
-
BCC6889
QX 314 bromide
QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker.
-
BCC7326
QX 314 chloride
QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
-
BCC7844
Ralfinamide mesylate
Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain.
-
BCC7847
Sipatrigine
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke.
-
BCC6179
TC-N 1752
1211866-85-1
-
BCN1035
Tetrodotoxin
Tetrodotoxin is a highly selective <b>sodium channel</b> blocker, with <b>IC<sub>50</sub></b> of 33 nM for <b>Nav1.6</b>.
-
BCC2156
Valproic acid sodium salt (Sodium valproate)
Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
-
BCN2609
Vinpocetine
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
-
BCC1048
β-Pompilidotoxin
Slows neuronal Na<sup>+</sup> channel inactivation
-
BCC5078
Rufinamide
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).


